Jim Cramer
-
Health News
We’re buying more of this health-care company amid an overdone sell-off
[ad_1] Shortly after the opening bell, we will be buying 140 shares of Abbott Laboratories at roughly $112. Following the…
Read More » -
Health News
Nvidia stomps the bears. Plus, Cramer’s thoughts on 2 struggling portfolio names
[ad_1] Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in…
Read More » -
Health News
Jim Cramer defends Elon Musk’s use of ketamine for depression: The CEO ‘saved a lot of lives’
[ad_1] CNBC’s Jim Cramer said Tuesday that Elon Musk’s disclosure that he takes prescription ketamine for depression was courageous and…
Read More » -
Health News
Here is Eli Lilly’s competitive edge in GLP-1 obesity drugs and Abbott’s secondary play
[ad_1] Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in…
Read More » -
Health News
Jim Cramer says buy this data center equipment firm despite its weak guidance
[ad_1] Vertiv Holdings : The data center equipment maker, whose shares have roughly quadrupled over the past year, issued guidance…
Read More » -
Health News
Portfolio health care name turns its luck around thanks to management’s AI push
[ad_1] Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s…
Read More » -
Health News
Obesity and Alzheimer’s drugs pack one-two punch to power Eli Lilly higher in 2024
[ad_1] Investor optimism for Eli Lilly ‘s diabetes and obesity treatments in 2023 lifted the stock to its seventh annual…
Read More » -
Health News
Here’s a rapid-fire update on all 33 stocks in our portfolio, including those Cramer would buy on dips
[ad_1] Jim Cramer ran through all 33 stocks in his Charitable Trust portfolio during the December edition of the CNBC…
Read More » -
Health News
Prescriptions for Eli Lilly’s new weight-loss drug get off to a strong start and confirm bright outlook
[ad_1] The launch of Eli Lilly ‘s weight-loss drug Zepbound — a key pillar of our investment thesis in the…
Read More » -
Health News
Weight gain after stopping Eli Lilly’s new obesity treatment should help, not hurt the stock
[ad_1] Some Eli Lilly investors appear concerned about clinical trial data that showed patients regained weight after they stopped taking…
Read More »